GLAXOSMITHKLINE PLC Form 6-K February 22, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 22 February 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

(the Company)		
GlaxoSmithKline plc (the 'Company')		
Transaction notification		
<ol> <li>Details of PDMR/person closely association</li> <li>Name</li> <li>Position/status</li> <li>Initial notification/ amendment</li> </ol>	Mr R G Connor President, Global Manufacturing & Supply Initial Notification	
<ol> <li>Details of the issuer, emission allowance platform, auctioneer or auction monitor</li> <li>a) Name</li> <li>b) LEI</li> <li>Details of the transaction(s): section to b</li> <li>3. instrument; (ii) each type of transaction; place where transaction(s) has been cond</li> </ol>	GlaxoSmithKline plc 5493000HZTVUYLO1D793 e repeated for (i) each type of (iii) each date; and (iv) each	
a) Description of the financial instrument	each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.	
c) Price(s) and volume(s)	Price(s) Volume(s) £0.0000 13,284 (Deferred) £0.0000 4,428 (Matching)	
<ul> <li>Aggregated information</li> <li>Aggregated volume Price</li> <li>Date of the transaction</li> <li>Place of the transaction</li> </ul>	17,712 £0.0000 2017-02-21 n/a	

GlaxoSmithKline plc

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1.	Details of PDMR/person closely associa	ted with them ('PCA')
a)	Name	Mr R G Connor
1 \		President, Global
b)	Position/status	Manufacturing & Supply
	Initial notification/	<b>c 1 1 1</b>
c)	amendment	Initial Notification
_	Details of the issuer, emission allowance	market participant, auction
2.	platform, auctioneer or auction monitor	
a)		GlaxoSmithKline plc
	LEI	5493000HZTVUYLO1D793
0)	Details of the transaction(s): section to b	
3.	instrument; (ii) each type of transaction;	
5.	place where transaction(s) has been cond	
	place where transaction(3) has been cone	Ordinary shares of 25 pence
		each ('Ordinary Shares')
a)	Description of the financial instrument	caen (Ordinary Shares)
<i>a)</i>	Description of the financial instrument	ISIN: GB0009252882
		ISHA: GB0009252002
		The sale of Ordinary Shares to
		-
		meet tax liabilities on nil-cost
		meet tax liabilities on nil-cost options over Ordinary Shares
b)	Nature of the transaction	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February
b)	Nature of the transaction	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's
b)	Nature of the transaction	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan -
b)	Nature of the transaction	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching
b)	Nature of the transaction	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
b)	Nature of the transaction	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s)
,	Nature of the transaction Price(s) and volume(s)	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 6,369 (Deferred)
,		meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s)
,	Price(s) and volume(s)	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 6,369 (Deferred)
c)	Price(s) and volume(s) Aggregated information	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 6,369 (Deferred) £16.3575 2,124 (Matching)
,	Price(s) and volume(s)	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 6,369 (Deferred) £16.3575 2,124 (Matching) 8,493
c) d)	Price(s) and volume(s) Aggregated information Aggregated volume Price	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 6,369 (Deferred) £16.3575 2,124 (Matching) 8,493 £16.3575
c) d)	Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 6,369 (Deferred) £16.3575 2,124 (Matching) 8,493 £16.3575 2017-02-21
c) d)	Price(s) and volume(s) Aggregated information Aggregated volume Price	meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 6,369 (Deferred) £16.3575 2,124 (Matching) 8,493 £16.3575

1.	1. Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr S A Hussain	
b)	Position/status	President, Global	
		Pharmaceuticals	
c)	Initial notification/	Initial Notification	
	amendment	Initial Notification	
2	$_{2}$ Details of the issuer, emission allowance market participant, auction		
<sup>2</sup> . platform, auctioneer or auction monitor			
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	

(XLON)

3.

# Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.0000 9,743 (Deferred) £0.0000 3,248 (Matching)	
d) e)	Aggregated information Aggregated volume Price Date of the transaction	12,991 £0.0000 2017-02-21	

- /			
f)	Place of the transaction	n/a	

1. a)	Details of PDMR/person closely associate Name	ted with them ('PCA') Mr S A Hussain	
	Position/status	President, Global Pharmaceuticals	
c)	Initial notification/ amendment	Initial Notification	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market participant, auction	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
,	Details of the transaction(s): section to be repeated for (i) each type of		
3.			
	place where transaction(s) has been conducted		
	-	Ordinary shares of 25 pence each ('Ordinary Shares')	
a)	Description of the financial instrument	· · · ·	
,		ISIN: GB0009252882	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February	

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
Price(s) and volume(s)	Price(s) Volume(s) £16.4650 4,234 (Deferred) £16.4750 1,412 (Matching)
Aggregated information Aggregated volume Price	5,646 f16 4675

	£10.4075
e) Date of the transaction	2017-02-21
Place of the transaction	London Stock Exchange
1)	(XLON)

c)

d)

1.	Details of PDMR/person closely associat	ted with them $(\mathbf{PCA})$
	Name	Dr P J T Vallance
	Position/status	President, R&D
	Initial notification/	
c)	amendment	Initial Notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to be	e repeated for (i) each type of
3.		
	place where transaction(s) has been cond	lucted
		Ordinary shares of 25 pence
		each ('Ordinary Shares')
a)	Description of the financial instrument	
		ISIN: GB0009252882
- 1	Nature of the transaction Price(s) and volume(s)	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £0.0000 26,863 (Deferred) £0.0000 8,954 (Matching)
	Aggregated information	
d)	Aggregated volume Price	35,817
	Aggregated volume Flice	£0.0000
e)	Date of the transaction	2017-02-21
~		

n/a

	Details of PDMR/person closely associat	
	Name	Dr P J T Vallance
b)	Position/status	President, R&D
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market participant, auction
a)	Name	GlaxoSmithKline plc
	LEI	5493000HZTVUYLO1D793
0)	Details of the transaction(s): section to be	
3	instrument; (ii) each type of transaction;	
5.	place where transaction(s) has been cond	
	place where transaction(s) has been cond	Ordinary shares of 25 pence
		each ('Ordinary Shares')
a)	Description of the financial instrument	caen (Ordinary Shares)
<i>a)</i>	Description of the inflateral institution	ISIN: GB0009252882
,	Nature of the transaction Price(s) and volume(s)	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. Price(s) Volume(s) £16.3575 12,879 (Deferred) £16.3575 4,294 (Matching)
d) e)	Aggregated information Aggregated volume Price Date of the transaction	17,173 £16.3575 2017-02-21
f)	Place of the transaction	London Stock Exchange (XLON)

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: February 22, 2017

## By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc